Other Events ·
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen failed to meet its primary endpoint, showing…
NVSNovartis AG
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen failed to meet its primary endpoint, showing no reduction in cardiovascular events compared to placebo despite achieving lower lipoprotein (a) levels. The study enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease. Novartis stated the findings provide important evidence on the relationship between Lp(a) lowering and outcomes but did not demonstrate risk reduction in the overall population. Pelacarsen is an investigational antisense oligonucleotide developed under a license from Ionis Pharmaceuticals to inhibit Lp(a) production. Novartis AG operates as an innovative medicines company focused on discovering, developing, and commercializing pharmaceutical products globally.